HBV genotype B/C and response to lamivudine therapy:a systematic review
- VernacularTitle:拉米夫定治疗B/C基因型乙肝病毒疗效及其相关性的Meta分析
- Author:
Sisi WU
;
Shanshan ZHU
;
Yanqiu SHI
- Publication Type:Journal Article
- Keywords:
hepatitis B;
lamivudine;
meta-analysis;
genotype B virus;
genotype C virus
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;35(10):178-182
- CountryChina
- Language:Chinese
-
Abstract:
Objective To perform a meta-analysis on the association of of genotype B/C and HBV DNA conversion of negative or HBeAg clearance to lamivudine therapy.Methods Several databases (PubMed, Web of Science, Science Direct, and CNKI Database) were searched from 1966 to 2012 for all publications on the association between genotype B/C and response to LAM therapy.The articles were selected according to the protocol previously designed.Meta analysis using Revman 5 software.Results Finally, 19 RCTs were retrieved involving 3148 patients for the subsequent meta-analysis. Among them, 10 articles (n=1860) look at HBV DNA and 9 (n=1288) at HbeAg clearance.For HBV DNA conversion of negative, the overall RR (95% CI) associated with genotype B/C was 1.07(0.98-1.17). Of the nine analyzed trials, HBeAg clearance was observed in genotype B group as compared with that genotype C group, the overall RR (95% CI) was 1.27 (0.94-1.71).Conclusion Meta-analysis indicates that genotype B/C is not associated with response to LAM therapy.Further mechanism researches are required to clarify.Large-scale population studies in multicountries are also necessary to evaluate the influence of HBV genotypes in hepatitis B progression and antiviral treatment.
